Increased brain radioactivity by intranasal 32P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 1373-1385

  Perez, Ana Paula ^a   Mundiña Weilenmann, Cecilia ^b   Romero, Eder Lilia ^a   Morilla, Maria Jose ^a  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

Dendrimers; Gel; Mucosa; Nucleic acids; Olfactory bulb

Indexed keywords

CARBOMER; CHITOSAN; DENDRIMER; DRUG CARRIER; IN SITU FORMING MUCOADHESIVE GEL; LIPOFECTAMINE; PHOSPHORUS 32; POLOXAMER; POLY(AMIDOAMINE) G7 DENDRIMER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; PAMAM STARBURST; PHOSPHORUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN RADIOACTIVITY; CHEMICAL PHENOMENA; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG RELEASE; FLOW KINETICS; GELATION; GENE SILENCING; HISTOPATHOLOGY; IN VITRO STUDY; ISOTOPE LABELING; MALE; MUCUS; NEWTONIAN PSEUDOPLASTIC BEHAVIOR; NON NEWTONIAN PSEUDOPLASTIC BEHAVIOR; NONHUMAN; RADIOACTIVITY; RAT; TEMPERATURE; TOXICITY TESTING; VISCOELASTICITY; ANIMAL; BRAIN; BRAIN LEVEL; CHEMISTRY; CYTOCHEMISTRY; DRUG EFFECT; GEL; INTRANASAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; NOSE MUCOSA; SPRAGUE DAWLEY RAT; VISCOSITY; YOUNG MODULUS;

RATTUS;

ADMINISTRATION, INTRANASAL; ANIMALS; BRAIN; BRAIN CHEMISTRY; CHITOSAN; DENDRIMERS; ELASTIC MODULUS; GELS; HISTOCYTOCHEMISTRY; MALE; NASAL MUCOSA; PHOSPHORUS ISOTOPES; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; TEMPERATURE; VISCOSITY;

EID: 84862315161     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S28261     Document Type: Article

References (57)

1. Lansley AB, Martin GP. Nasal drug delivery. In: Hillery AM, Lloyd AW, Swarbrick J. Drug Delivery and Targeting. Boca Raton, FL: CRC Press;2001:237-268.
2. Thorne RG, Emory CR, Ala TA, Frey II WH. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res. 1995;692:278-282.
3. Frey II WH, Liu JCX, Thorne RG, Fawcett JR, Ala TA, Rahman YE. Delivery of 125I-NGF to the brain via the olfactory route. Drug Deliv. 1997;4:87-92.
4. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2011. Epub Nov 15.
5. Pardridge WM. shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev. 2007;59(2-3):141-152.
6. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000;11(1):1-18.
7. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol. 2004;56:3-17.
8. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009;379:146-157.
9. Dhuria SV, Hanson LR, Frey II WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99:1654-1673.
10. Baker H, Genter MB. The olfactory system and the nasal mucosa as portals of entry of viruses, drugs, and other exogenous agents into the brain. In: Doty RL. Handbook of Olfaction and Gustation. New York: Marcel Dekker; 2003:549-573.
11. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptide: a transnasal approach to the human brain. Nat Neurosci. 2002;5:514-516.
12. Ermisch A, Barth T, Rühle HJ, Skopková J, Hrbas P, Landgraf R. On the blood-brain barrier to peptides: accumulation of labelled vasopressin, DesGlyNH2-vasopressin and oxytocin by brain regions. Endocrinol Exp. 1985;19:29-37.
13. Kang YS, Park JH. Brain uptake and the analgesic effect of oxytocin-its usefulness as an analgesic agent. Arch Pharm Res. 2000;23:391-395.
14. Boudreau RL, Davidson BL. RNAi therapeutics for CNS disorders. Brain Res. 2010;1338:112-121.
15. Uno Y, Piao W, Miyata K, Nishina K, Mizusawa H, Yokota T. Highdensity lipoprotein facilitates in vivo delivery of d-tocopherol-conjugated short-interfering RNA to the brain. Hum Gene Ther. 2011; 22(6): 711-719.
16. Nakajima H, Kubo T, Semi Y, et al. A rapid, targeted, neuron-selective, in vivo knockdown following a single intracerebroventricular injection of a novel chemically modified siRNA in the adult rat brain. J Biotechnol. 2012;157(2):326-333.
17. Al-Jamal KT, Gherardini L, Bardi G, et al. Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing. Proc Natl Acad Sci U S A. 2011;108(27):10952-10957.
18. Bonoiu AC, Bergey EJ, Ding H, et al. Gold nanorod-siRNA induces efficient in vivo gene silencing in the rat hippocampus. Nanomedicine (Lond). 2011;6(4):617-630.
19. Cheng D, Cao N, Chen J, Yu X, Shuai X. Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat. Biomaterials. 2012;33(4): 1170-1179.
20. Stiles D, Zhang Z, Ge P, et al. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol. 2011. Epub Nov 19.
21. Akaneya Y, Jiang B, Tsumoto T. RNAi induced gene silencing by local electroporation in targeting brain region. J Neurophysiol. 2005;93:594-602.
22. Xia CF, Zhang Y, Boado RJ, Pardridge WM. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res. 2007;24(12):2309-2316.
23. Kim SS, Ye C, Kumar P, et al. Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther. 2010;18(5):993-1001.
24. Jin J, Bae KH, Yang H, et al. In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug Chem. 2011;22(12):2568-2572.
25. Kuwahara H, Nishina K, Yoshida K, et al. Efficient in vivo delivery of siRNA into brain capillary endothelial cells along with endogenous lipoprotein. Mol Ther. 2011;(12):2213-2221.
26. Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007;448:39-43.
27. Kim ID, Kim SW, Lee JK. Gene knockdown in the olfactory bulb, amygdala, and hypothalamus by intranasal siRNA administration. Korean J Anat. 2009;42:285-292.
28. Perez AP, Romero EL, Morilla MJ. Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents. Int J Pharm. 2009;380(1-2):189-200.
29. Charlton S, Jones NS, Davis SS, Illum L. Distribution and clearance of bioadhesive formulations from the olfactory region in man: Effect of polymer type and nasal delivery device. Eur J Pharm Sci. 2007;30:295-302.
30. Perez AP, Cosaka ML, Romero EL, Morilla MJ. Uptake and intracellular traffic of siRNA dendriplexes in glioblastoma cells and macrophages. Int J Nanomedicine. 2011;6:2715-2728.
31. Jones DS, Bruschi ML, De Freitas O, Gremiao MPD, Lara EHG, Andrews GP. Rheological, mechanical and mucoadhesive properties of thermoresponsive, bioadhesive binary mixtures composed of poloxamer 407 and carbopol 974P designed as platforms for implantable drug delivery systems for use in the oral cavity. Int J Pharm. 2009;372: 49-58.
32. Gratieri T, Gelfuso GM, Rocha EM, Sarmento VH, de Freitas O, Lopez RF. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm. 2010;75:186-193.
33. Jones DS, Brown AF, Woolfson AD. Solute and solvent effects on the thermorheological properties of poly(oxyethylene)-poly(oxypropylene) block copolymers: implications for pharmaceutical dosage form design. J Appl Polym Sci. 2003;87:1016-1026.
34. Jones DS, Brown AF, Woolfson AD. Rheological characterization of bioadhesive, antimicrobial, semisolids designed for the treatment of periodontal diseases: transient and dynamic viscoelastic and continuous shear analysis. J Pharm Sci. 2001;90:1978-1990.
35. Malek A, Czubayko F, Aigner A. PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy. J Drug Target. 2008;16:124-139.
36. Martinac A, Filipović-Griĉć J, Voinovich D, Perissutti B, Franceschinis E. Development and bioadhesive properties of chitosan-ethylcellulose microspheres for nasal delivery. Int J Pharm. 2005;291:69-77.
37. Jansson B, Hägerström H, Fransén N, Edsman K, Björk E. The influence of gellan gum on the transfer of fluorescein dextran across rat nasal epithelium in vivo. Eur J Pharm Biopharm. 2005;59(3):557-564.
38. Bindseil E, Bechgaard E, Jorgensen L, Larsen R. Morphological examination of rabbit nasal mucosa after exposure to acetylsalicylic acid, glycofurol75 and ephedrine. Int J Pharm. 1995;119:37-46.
39. Collaud S, Peng QA, Gurny R, Lange N. Thermosetting gel for the delivery of 5-aminolevulinic acid esters to the cervix. J Pharm Sci. 2008;97:2680-2690.
40. Hartikka J, Geall A, Bozoukova V, et al. Physical characterization and in vivo evaluation of poloxamer-based DNA vaccine formulations. J Gene Med. 2008;10:770-782.
41. Jeong B, Kim SW, Bae YH. Thermosensitive sol-gel reversible hydrogels. Adv Drug Deliv Rev. 2002;54:37-51.
42. El Kamel AH. In vitro and in vivo evaluation of pluronic F127-based ocular delivery system for timolol maleate. Int J Pharm. 2002;241:47-55.
43. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. Evaluation of clearance characteristics of bioadhesive systems in humans. Int J Pharm. 1999;78:55-65.
44. Tas C, Ozkan CK, Savaser A, Ozkan Y, Tasdemir U, Altunay H. Nasal absorption of metoclopramide from different Carbopol 981 based formulations: In vitro, ex vivo and in vivo evaluation. Eur J Pharm Biopharm. 2006;64:246-254.
45. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med. 1997;155:2018-2023.
46. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Del Rev. 2005;57(11):1640-1665.
47. Dong Z, Katsumi H, Sakane T, Yamamoto A. Effects of polyamidoamine (PAMAM) dendrimers on the nasal absorption of poorly absorbable drugs in rats. Int J Pharm. 2010;393:244-252.
48. van de Water FM, Boerman OC, Wouterse AC, Peters JGP, Russel FG, Masereeuw R. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos. 2006;34:1393-1397.
49. Gao S, Dagnaes-Hansen F, Nielsen EJB, et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther. 2009;17:1225-1233.
50. Han In-K, Kim MY, Byun H-M, et al. Enhanced brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy. J Mol Med. 2007;85:75-83.
51. Merkus FW, van den Berg MP. Can nasal drug delivery bypass the blood-brain barrier? Questioning the direct transport theory. Drugs R D. 2007;8:133-144.
52. Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect. 2005;113:823-839.
53. 3 particles into the brain: micro-distribution, chemical states, and histopathological observation. Biol Trace Elem Res. 2007;118:233-243.
54. 2) nanoparticles. Toxicology. 2008;254:82-90.
55. van Rooy I, Cakir-Tascioglu S, Hennink WE, Storm G, Schiffelers RM, Mastrobattista E. In vivo methods to study uptake of nanoparticles into the brain. Pharm Res. 2011;28:456-471.
56. Huang RQ, Ke WL, Qu YH, Zhu JH, Pei YY, Jiang C. Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain. J Biomed Sci. 2007;14(1):121-128.
57. Huang RQ, Ke WL, Liu Y, Jiang C, Pei YY. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials. 2008;29:238-246.